ghazaleh khalili-tanha

Ms. ghazaleh khalili-tanha


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AAAlireza Asadnia
Alireza Asadnia
ENElham Nazari
Elham Nazari
LGLadan Goshayeshi
Ladan Goshayeshi
NZNima Zafari
Nima Zafari
MMMehrdad Moetamani-Ahmadi
Mehrdad Moetamani-Ahmadi
AAAmir Avan
Amir Avan
Introduction: Colorectal cancer (CRC) is a common cancer associated with poor outcomes, underscoring a need for the identification of novel prognostic and therapeutic targets to improve outcomes. This study aimed to identify genetic variants and differentially expressed genes (DEGs) using genome-wide DNA and RNA sequencing followed by validation in a large cohort of patients with CRC. Methods: Whole genome and gene expression profiling were used to identify DEGs and genetic alterations in 146 patients with CRC. Gene Ontology, Reactom, GSEA, and Human Disease Ontology were employed to study the biological process and pathways involved in CRC. Survival analysis on dysregulated genes in patients with CRC was conducted using Cox regression and Kaplan–Meier analysis. The STRING database was used to construct a protein–protein interaction (PPI) network. Moreover, candidate genes were subjected to ML-based analysis and the Receiver operating characteristic (ROC) curve. Subsequently, the expression of the identified genes was evaluated by Real-time PCR (RT-PCR) in another cohort of 64 patients with CRC. Gene variants affecting the regulation of candidate gene expressions were further validated followed by Whole Exome Sequencing (WES) in 15 patients with CRC. Results: A total of 3576 DEGs in the early stages of CRC and 2985 DEGs in the advanced stages of CRC were identified. ASPHD1 and ZBTB12 genes were identified as potential prognostic markers. Moreover, the combination of ASPHD and ZBTB12 genes was sensitive, and the two were considered specific markers, with an area under the curve (AUC) of 0.934, 1.00, and 0.986, respectively. The expression levels of these two genes were higher in patients with CRC. Moreover, our data identified two novel genetic variants—the rs925939730 variant in ASPHD1 and the rs1428982750 variant in ZBTB1—as being potentially involved in the regulation of gene expression. Conclusions: Our findings provide a proof of concept for the prognostic values of two novel genes—ASPHD1 and ZBTB12—and their associated variants (rs925939730 and rs1428982750) in CRC, supporting further functional analyses to evaluate the value of emerging biomarkers in colorectal cancer.

30 September 2024 in International Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
HJHamid Jamialahmadi
Hamid Jamialahmadi
GKghazaleh khalili-tanha
ghazaleh khalili-tanha
MRMostafa Rezaei-Tavirani
Mostafa Rezaei-Tavirani
ENElham Nazari
Elham Nazari
Context: Metabolic disorders are a growing global concern, especially in developed countries, due to their increasing prevalence. Serum lipid profiles, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL), are commonly used clinical biomarkers for monitoring the progression of these metabolic abnormalities. In recent decades, hydrogen-rich water (HRW) has gained attention as a safe and effective treatment, with regulatory effects on lipid peroxidation and inflammatory responses in clinical trials. Objectives: This systematic review and meta-analysis aim to evaluate the effectiveness of HRW therapy on blood lipid profiles in randomized controlled trials (RCTs) for metabolic disorders. Methods: Following the PRISMA guidelines, a search for RCT studies was conducted in the PubMed, Web of Science, Embase, and Google Scholar databases up to January 2024. Eight studies that met all eligibility criteria, including RCTs involving metabolic dysfunctions and evaluations of lipid profiles, were included for further analysis. Data extraction was followed by quality evaluation using the Jadad scoring system. Meta-analysis was conducted using STATA software. Results: The eight selected RCTs included a total of 357 patients with various metabolic disorders. All studies showed either no or low risk of bias. The overall levels of TG [95% CI: -0.27 (-0.47, -0.07)], TC [95% CI: -0.07 (-0.32, -0.18)], and LDL [95% CI: -0.06 (-0.28, 0.15)] demonstrated slight decreases across the studies. However, there was some heterogeneity in HDL levels [95% CI: -0.11 (-0.37, 0.14)] among the studies (I² = 37.32%). Meta-regression analysis further indicated a positive association between the outcomes and the duration of the intervention as a moderating factor. Conclusions: Hydrogen-rich water demonstrated modest lipid-lowering effects in patients with metabolic disorders. However, due to the observed heterogeneity in HDL variations, further long-term trials involving larger populations are needed to clarify these inconsistencies.

10 October 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SNSeyedeh Elnaz Nazari
Seyedeh Elnaz Nazari
ATAlexander Tarnava
Alexander Tarnava
NKNima Khalili-Tanha
Nima Khalili-Tanha
Mahdieh DarroudiMahdieh Darroudi
Mahdieh Darroudi
GKghazaleh khalili-tanha
ghazaleh khalili-tanha
Tyler W. LeBaronTyler W. LeBaron
Tyler W. LeBaron
Skeletal muscle atrophy is associated with poor quality of life and disability. Thus, finding a new strategy for the prevention and treatment of skeletal muscle atrophy is very crucial. This study aimed to investigate the therapeutic potential of hydrogen-rich water (HRW) on muscle atrophy in a unilateral hind limb immobilization model. Thirty-six male Balb/C mice were divided into control (without immobilization), atrophy, and atrophy + hydrogen-rich water (HRW). Unilateral hind limb immobilization was induced using a splint for 7 days (atrophy) and removed for 10 days (recovery). At the end of each phase, gastrocnemius and soleus muscle weight, limb grip strength, skeletal muscle histopathology, muscle fiber size, cross-section area (CSA), serum troponin I and skeletal muscle IL-6, TNF-α and Malondialdehyde (MDA), and mRNA expression of NF-κB, BAX and Beclin-1 were evaluated. Muscle weight and limb grip strength in the H2-treated group were significantly improved during the atrophy phase, and this improvement continued during the recovery period. Treatment by HRW increased CSA and muscle fiber size and reduced muscle fibrosis, serum troponin I, IL-6, TNF-α and MDA which was more prominent in the atrophy phase. These data suggest that HRW could improve muscle atrophy in an immobilized condition and could be considered a new strategy during rehabilitation.

19 May 2025 in Current Nutrition Reports
Verified
Journal Article
Closed access
PDF file
MSMahdi Soroushianfar
Mahdi Soroushianfar
GAGoli Asgari
Goli Asgari
FAFatemeh Afzali
Fatemeh Afzali
AFAtiyeh Falahat
Atiyeh Falahat
MSMohammad Soroush
Mohammad Soroush
ENElham Nazari
Elham Nazari

17 December 2025 in Antonie van Leeuwenhoek
Verified
Journal Article
Closed access
PDF file
MAMelika Abrishami
Melika Abrishami
MSMohadeseh Sabouri
Mohadeseh Sabouri
FJFereshte Joneidi
Fereshte Joneidi
ZHZahra Haghshenas
Zahra Haghshenas
GKghazaleh khalili-tanha
ghazaleh khalili-tanha
ENElham Nazari
Elham Nazari

26 May 2025 in Current Nutrition Reports
Verified
Journal Article
Open access
PDF file
MSMahdi Soroushianfar
Mahdi Soroushianfar
GAGoli Asgari
Goli Asgari
FAFatemeh Afzali
Fatemeh Afzali
AFAtiyeh Falahat
Atiyeh Falahat
MBMohammad Soroush Mansoor Baghahi
Mohammad Soroush Mansoor Baghahi
ENElham Nazari
Elham Nazari